Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. (Q51978470)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 August 2007

Language	Label	Description	Also known as
English	Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group.	scientific article published on 9 August 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Daisuke Tomizawa

1

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

author name string

Koh K

2

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Sato T

3

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Kinukawa N

4

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Morimoto A

5

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Isoyama K

6

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Kosaka Y

7

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Oda T

8

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Oda M

9

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Hayashi Y

10

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Eguchi M

11

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Horibe K

12

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Nakahata T

13

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Mizutani S

14

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Ishii E

15

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

publication date

9 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

21

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

11

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

2258-2263

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

Treatment of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Marrow transplantation following busulfan and cyclophosphamide as treatment for translocation (4;11) acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow transplantation following busulfan, cyclophosphamide and high dose cytosine-arabinoside as treatment for infants with translocation (4;11) acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404903

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404903

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17690691

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51978470&oldid=2211378767"